<DOC>
	<DOCNO>NCT01536015</DOCNO>
	<brief_summary>The primary purpose demonstrate superiority Rotigotine Placebo motor symptom use subject symptoms Gastrointestinal Dysfunction . Hypothesis : Rotigotine decrease OFF time compare Placebo .</brief_summary>
	<brief_title>Effect Rotigotine Motor Symptoms Patients With Advanced Parkinson 's Disease ( PD ) With Motor Fluctuations Symptoms Gastrointestinal Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subject inform give ample time opportunity think his/her participation study give his/her write informed consent Institutional Review Board approve consent form Subject willing able comply study requirement ( protocol , visit schedule , procedure , medication application ) Subject male female ≥ 30 year age Subject Idiopathic Parkinson 's Disease 3 year duration , define cardinal sign , bradykinesia , plus presence least 1 follow : rest tremor , rigidity , impairment postural reflex ; without know suspected cause Parkinsonism Subject Hoehn &amp; Yahr stage score II IV Subject must stable dose Ldopa , either shortacting sustain release ( combination Benserazide Carbidopa ) , least 200 mg/day administer least 2 intake , least 21 day prior start Parkinson 's diary Subject must able differentiate `` '' `` '' state ( thereby able recognize Time To `` On '' ( TTON ) ) , willing able accurately complete Parkinson 's Disease subject diary designate day ( assistance caregiver , require ) Subject must complete 6 Parkinson 's diary period 6 day , 4 6 Parkinson 's diary `` valid '' determine investigator . The `` valid '' Parkinson 's diary confirm subject average least 2.5 h/day spend `` '' state Subject receive Monoamine Oxidase ( MAO ) B Inhibitor ( eg , Selegiline Rasagiline ) , nMethyldAspartate Antagonist ( eg , Amantadine ) , allow antiParkinson medication stable dose least 21 day prior start Parkinson 's diary anticipate maintain dose duration study Subject clinical symptom Gastrointestinal Dysfunction ( GID ) confirm least 1 follow •Parkinson 's diseaserelated GI symptom per Gastrointestinal Degenerative Scale ( GIND ) Scale : defecatory dysfunction , constipation , excessive gas , abdominal pain , bloating , nausea , vomit , anorexia , early satiety , weight loss ( except sialorrhea dysphagia ) Female subject childbearing potential must agree use 1 follow contraceptive method : oral contraceptive , intrauterine device , doublebarrier method , throughout study 2 week removal study medication Subject previously participate study Subject participate another study investigational medicinal product ( IMP ) medical device within last 30 day currently participate another study IMP medical device Subject Atypical Parkinsonian Syndrome due drug ( eg , Metoclopramide , Flunarizine ) , Metabolic Neurogenetic Disorders ( eg , Wilson 's Disease ) , Encephalitis , Cerebrovascular Disease , Degenerative Disease ( eg , Progressive Supranuclear Palsy ) Subject history Pallidotomy , Thalamotomy , Deep Brain Stimulation , Fetal Tissue Transplant Subject Dementia , Active Psychosis , Hallucinations Subject exhibit Dopaminergic Dysregulation Syndrome Subject receive therapy certain medication specific timeframe specify protocol Subject history chronic Gastrointestinal ( GI ) Disease relate Parkinson 's disease judgement investigator may affect ability subject participate study ( ie , Irritable Bowel Syndrome , Diverticulitis , Crohn 's Disease , etc ) GI/abdominal surgery ( except Appendectomy , Hysterectomy , Cholecystectomy ) Subject GI surgery 3 month prior Screening Visit Subject current diagnosis Epilepsy , history seizure adult , history stroke Transient Ischemic Attack within 1 year prior Screening Visit Subject clinically relevant Hepatic Renal Dysfunction Subject clinically relevant Cardiac Dysfunction ( cardiac disorder opinion investigator would put subject risk clinically relevant arrhythmia ) Subject Myocardial Infarction within last 1 year prior Screening Visit Subject history Symptomatic ( Asymptomatic ) Orthostatic Hypotension Subject Systolic Blood Pressure ( BP ) &lt; 105 mmHg Screening Visit Subject history chronic alcohol drug abuse within prior 6 month Female subject pregnant lactating Subject ( male female ) child bear potential surgically sterile use adequate birth control method Subject evidence Impulse Control Disorder accord Modified Minnesota Impulsive Disorders Interview ( mMIDI ) Screening Visit Subject lifetime history suicide attempt ( include active attempt , interrupt attempt , aborted attempt ) , suicidal ideation past 6 month indicate positive response ( 'Yes ' ) either Question 4 Question 5 ColumbiaSuicide Severity Rating Scale ( CSSRS ) Screening Visit Subject significant skin disease/condition would make transdermal drug use inappropriate , include history skin sensitivity adhesives transdermal medication Subject know hypersensitivity component Rotigotine patch , include Sodium Metabisulfite Subject medical , psychiatric , cognitive condition , laboratory abnormality would , opinion investigator , jeopardize compromise subject 's wellbeing ability participate study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro®</keyword>
	<keyword>Levodopa</keyword>
	<keyword>Gastrointestinal Dysfunction</keyword>
</DOC>